利妥昔单抗、甲氨蝶呤、异环磷酰胺和长春新碱(R-MIV)诱导免疫化疗治疗原发性中枢神经系统淋巴瘤的安全性和有效性,包括近期COVID-19大流行经验
该研究回顾性报告了64例原发性中枢神经系统淋巴瘤患者接受R-MIV诱导方案(利妥昔单抗、甲氨蝶呤、异环磷酰胺、长春新碱)的结局,中位年龄58岁,体能状态评分2分(PS 3占22%)。总缓解率73%(46/63),3-4级血液学毒性低,3例(4.7%)死于治疗相关毒性。结论认为R-MIV方案在常规实践中可行、有效且安全,即使在COVID-19大流行期间。
要点
- R-MIV方案每2周给予大剂量甲氨蝶呤3.5 g/m²联合异环磷酰胺,利妥昔单抗每周一次共6次。
- 总缓解率73%(46/63),另17.5%(11/63)基线无可见病灶;3-4级中性粒细胞减少25%,血小板减少1%。
- 3例(4.7%)死于治疗相关毒性;两例合并SARS-CoV-2感染、巨细胞病毒再激活和水痘-带状疱疹病毒者死亡。
核心结论
- R-MIV方案在常规实践中可行、有效且安全,即使在COVID-19大流行期间。
研究设计与样本
- 报告64例原发性中枢神经系统淋巴瘤患者接受R-MIV诱导方案(利妥昔单抗、甲氨蝶呤、异环磷酰胺、长春新碱)的结局。
- 方案包括每2周给予大剂量甲氨蝶呤3.5 g/m²联合异环磷酰胺,利妥昔单抗每周一次共6次。
主要发现
- 64例患者中位年龄58岁,体能状态评分2分(PS 3占22%)。
- 经MRI/CT评估总缓解率为73%(46/63),另17.5%(11/63)基线无可见病灶。
- 3-4级血液学毒性:中性粒细胞减少25%,血小板减少1%。
- 3例(4.7%)死于治疗相关毒性;两例合并SARS-CoV-2感染、巨细胞病毒再激活和水痘-带状疱疹病毒者死亡。
- 50例(78%)符合巩固治疗条件;中位无进展生存和总生存未达到(中位随访44个月)。
临床怎么用
- 作者认为R-MIV方案在常规实践中可行、有效且安全,即使在COVID-19大流行期间。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical data on primary central nervous system (CNS) lymphoma (PCNSL) patients is mostly generated from prospective studies, and many frail real-world patients are not included. Recently,the diagnosis and treatment of PCNSL patients was confounded by the COVID-19 pandemic. In particular, treatment with high-dose cytarabine was linked to increased risk of pneumonia and virus persistence. We report on outcome of the induction regimen R-MIV (rituximab, methotrexate, ifosfamide, and vincristine) involving intensive administration of high-dose methotrexate (3.5 g/m2 ) with ifosfamide, every 2 weeks and rituximab once per week for six doses. The median age and performance status (PS) for 64 patients was 58 years and 2 (PS 3; 22%) respectively. The overall response rate by magnetic resonance imaging/computed tomography (MRI/CT) was 73% (n = 46/63), with an additional 17.5% (n = 11/63) patients without measurable disease at baseline. Grade 3-4 haematological toxicity was low for R-MIV (neutropenia: 25% and thrombocytopenia: 1%). Three patients (4.7%) died from treatment-related toxicity. Co-existence of SARS-CoV-2 infection with cytomegalovirus reactivation and the varicella-zoster virus in two patients was fatal. Fifty patients (78%) were eligible for consolidation. Median progression-free and overall survival were not reached (median follow-up: 44 months). In conclusion, the R-MIV regimen is feasible in routine practice, effective and safe, even during the COVID-19 pandemic.
引用
- Ostrowska B, Domanska-Czyz K, Romejko-Jarosinska J, et al. Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine (R-MIV) in patients with primary CNS lymphoma including recent COVID-19 pandemic experience. Br J Haematol. 2023. PMID: 36762710. doi:10.1111/bjh.18687
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。